- Jiangsu Hengrui’s full year net income reached 6.34 billion yuan, surpassing estimates of 6.01 billion yuan.
- The company’s revenue for the year was 27.98 billion yuan, exceeding the expected 27.03 billion yuan.
- A final dividend per share was declared at 20 RMB cents, slightly below the estimate of 22 RMB cents.
- Earnings per share for the year stood at 1.00 yuan.
- Net income witnessed a significant increase of 47.3% compared to the previous year.
- Market sentiment includes 30 buy ratings, 5 hold ratings, and 1 sell rating for the company’s stock.
Jiangsu Hengrui Medicine on Smartkarma
Analysts on Smartkarma are closely monitoring Jiangsu Hengrui Medicine, with a focus on recent developments in the pharmaceutical company. Tina Banerjee‘s analysis highlights Hengrui’s exclusive deal with Merck for HRS-5346, a potential game-changer in cardiovascular drugs, with substantial upfront and milestone payments. The company’s strong revenue growth and profit increase are also noted, setting the stage for its upcoming full-year results announcement.
Moreover, perspectives from Ke Yan, CFA, FRM, and Sumeet Singh compare Hengrui’s H-share listing to peers like Hansoh Pharma, indicating a premium valuation. In contrast, Xinyao (Criss) Wang adopts a more cautious stance, questioning Hengrui’s high valuation in the face of business transformation challenges. Brian Freitas discusses the potential index inclusion post H-share listing, with Jiangsu Hengrui Medicine aiming for a significant raise through its HKEX listing, signaling growth opportunities amidst market dynamics.
A look at Jiangsu Hengrui Medicine Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Jiangsu Hengrui Medicine shows promising long-term prospects. With high scores in Growth and Resilience, the company is positioned for future expansion and has demonstrated stability in challenging market conditions. Coupled with moderate scores in Value and Dividend, investors may find Jiangsu Hengrui Medicine to be a solid choice for sustained growth and potential returns.
Jiangsu Hengrui Medicine Co., Ltd. is a company that specializes in the development, manufacturing, and marketing of a diverse range of medicines and medicine packaging materials. Its product portfolio includes anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foil, and related items. With a strong focus on innovation and product quality, the company aims to meet the healthcare needs of its customers effectively.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
